Trial intelligence / Profile preview

DC-CIK Treatment in Stage II-III Nasopharyngeal Carcinoma

NCT01821495Phase 2Unknown

Sponsor
Guangxi Medical University
Start
May 2013
Primary completion
May 2018
Modality
Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
Countries
1
01

Overview

A Phase 2 trial of dendritic cell vaccine + cytokine-induced killer cells in nasopharyngeal carcinoma (NPC), sponsored by Guangxi Medical University. Status: unknown.

02

Drugs

dendritic cell vaccine + cytokine-induced killer cells
03

Conditions

nasopharyngeal carcinoma (NPC)

Beyond the preview

Go deeper on NCT01821495.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01821495.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call